204 related articles for article (PubMed ID: 30525751)
1. CD30+ T-cell lymphoproliferative disorders.
Martin JM; Wu H; Barta SK
Chin Clin Oncol; 2019 Feb; 8(1):4. PubMed ID: 30525751
[TBL] [Abstract][Full Text] [Related]
2. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
Kartan S; Johnson WT; Sokol K; Alpdogan O; Gru AA; Nikbakht N; Porcu P
Chin Clin Oncol; 2019 Feb; 8(1):3. PubMed ID: 30691273
[TBL] [Abstract][Full Text] [Related]
3. Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
Di Raimondo C; Parekh V; Song JY; Rosen ST; Querfeld C; Zain J; Martinez XU; Abdulla FR
Curr Hematol Malig Rep; 2020 Aug; 15(4):333-342. PubMed ID: 32435988
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the t(2;5) (p23;q35) translocation in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
Wood GS
Leuk Lymphoma; 1998 Mar; 29(1-2):93-101. PubMed ID: 9638979
[TBL] [Abstract][Full Text] [Related]
5. CD30-Positive Lymphoproliferative Disorders.
Nikolaenko L; Zain J; Rosen ST; Querfeld C
Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
[TBL] [Abstract][Full Text] [Related]
6. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
Kempf W; Kutzner H; Cozzio A; Sander CA; Pfaltz MC; Müller B; Pfaltz M
Br J Dermatol; 2008 Jun; 158(6):1280-7. PubMed ID: 18410414
[TBL] [Abstract][Full Text] [Related]
7. Primary cutaneous CD30+ lymphoproliferative disorders with DUSP22 translocation.
Montes-Moreno S
Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):136-139. PubMed ID: 38010388
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
Ferreira CR; Zhao S; Sanches JA; Miyashiro D; Cury-Martins J; Azevedo RS; Zerbini MCN; Natkunam Y; Gratzinger D
Diagn Pathol; 2019 Oct; 14(1):115. PubMed ID: 31640798
[TBL] [Abstract][Full Text] [Related]
9. Primary cutaneous CD30(+) lymphoproliferative disorders.
Wieser I; Tetzlaff MT; Torres Cabala CA; Duvic M
J Dtsch Dermatol Ges; 2016 Aug; 14(8):767-82. PubMed ID: 27509411
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous CD30-positive lymphoproliferative disorders with CD8 expression: a clinicopathologic study of 21 cases.
Plaza JA; Feldman AL; Magro C
J Cutan Pathol; 2013 Feb; 40(2):236-47. PubMed ID: 23189966
[TBL] [Abstract][Full Text] [Related]
11. Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation.
Davick JJ; Mutgi KAJ; Wanat KA; Link BK; Liu V
J Cutan Pathol; 2017 Aug; 44(8):703-712. PubMed ID: 28497585
[TBL] [Abstract][Full Text] [Related]
12. CD30-positive lymphoproliferative disorders-An Australian Clinical Practice Statement from the Peter MacCallum Cancer Centre.
Bhabha FK; McCormack C; Campbell BA; Lade S; Buelens O; Van Der Weyden C; Prince HM
Australas J Dermatol; 2023 May; 64(2):194-203. PubMed ID: 36892928
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders.
Vonderheid EC; Sajjadian A; Kadin ME
J Am Acad Dermatol; 1996 Mar; 34(3):470-81. PubMed ID: 8609262
[TBL] [Abstract][Full Text] [Related]
14. Characterization of primary cutaneous CD8+/CD30+ lymphoproliferative disorders.
Martires KJ; Ra S; Abdulla F; Cassarino DS
Am J Dermatopathol; 2015 Nov; 37(11):822-33. PubMed ID: 26485239
[TBL] [Abstract][Full Text] [Related]
15. How I treat primary cutaneous CD30
Shinohara MM; Shustov A
Blood; 2019 Aug; 134(6):515-524. PubMed ID: 31164331
[TBL] [Abstract][Full Text] [Related]
16. Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders.
Sciallis AP; Law ME; Inwards DJ; McClure RF; Macon WR; Kurtin PJ; Dogan A; Feldman AL
Mod Pathol; 2012 Jul; 25(7):983-92. PubMed ID: 22388754
[TBL] [Abstract][Full Text] [Related]
17. CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.
Prieto-Torres L; Rodriguez-Pinilla SM; Onaindia A; Ara M; Requena L; Piris MÁ
Haematologica; 2019 Feb; 104(2):226-235. PubMed ID: 30630983
[TBL] [Abstract][Full Text] [Related]
18. [Primary cutaneous CD30+ lymphoproliferative disorders].
Calzado-Villarreal L; Polo-Rodríguez I; Ortiz-Romero PL
Actas Dermosifiliogr; 2010 Mar; 101(2):119-28. PubMed ID: 20223154
[TBL] [Abstract][Full Text] [Related]
19. Primary cutaneous anaplastic large cell lymphoma.
Brown RA; Fernandez-Pol S; Kim J
J Cutan Pathol; 2017 Jun; 44(6):570-577. PubMed ID: 28342276
[TBL] [Abstract][Full Text] [Related]
20. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype.
Kummer JA; Vermeer MH; Dukers D; Meijer CJ; Willemze R
J Invest Dermatol; 1997 Nov; 109(5):636-40. PubMed ID: 9347791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
